Search

Displaying results 5051 - 5060 of 7600 in total
  1. Drug

    Cannabidiolic acid

    go.drugbank.com/drugs/DB19261
    Investigational

    Cannabidiolic acid is under investigation in clinical trial NCT04103814 (Effect of Topical CBD Cream for Degenerative Hallux Disorders).

  2. Drug

    Orbifloxacin

    go.drugbank.com/drugs/DB11443
    ExperimentalVet approved

    It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.

  3. Drug

    Fluclorolone acetonide

    go.drugbank.com/drugs/DB08973
    ApprovedWithdrawn

    Fluclorolone acetonide (INN) or flucloronide (USAN) is a topical corticosteroid. It is marketed under the brand names Cutanit and Topicon.

  4. Drug

    SIS-101-ADO

    go.drugbank.com/drugs/DB18085
    Experimental

    SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).[L48091]

  5. Drug

    Mecapegfilgrastim

    go.drugbank.com/drugs/DB19147
    Investigational

    Mecapegfilgrastim is under investigation in clinical trial NCT05463601 (Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer).

  6. Drug

    PXT 3003

    go.drugbank.com/drugs/DB16745
    Investigational

    PXT 3003 is in phase 3 clinical trials for the treatment of Charcot-Marie-Tooth disease type 1A in adults.

  7. Drug

    N-sulfoglucosamine sulfohydrolase recombinant

    go.drugbank.com/drugs/DB12722
    Investigational

    N-sulfoglucosamine sulfohydrolase recombinant is under investigation for the treatment of Mucopolysaccharidosis III and Sanfilippo Syndrome Type A (MPS IIIA).

  8. Drug

    Ganetespib

    go.drugbank.com/drugs/DB12047
    Investigational

    Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.

  9. Drug

    Technetium Tc-99m arcitumomab

    go.drugbank.com/drugs/DB00113
    Experimental

    Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99.

  10. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes.